High-throughput experimentation (HTE) has revolutionized the pharmaceutical industry, most notably allowing for rapid screening of compound libraries against therapeutic targets. The past decade has also witnessed the extension of HTE principles toward the realm of small-molecule process chemistry. Today, most major pharmaceutical companies have created dedicated HTE groups within their process development teams, invested in automation technology to accelerate screening, or both. The industry's commitment to accelerating process development has led to rapid innovations in the HTE space. This review will deliver an overview of the latest best practices currently taking place within our teams in process chemistry by sharing frequently studied transformations, our perspective for the next several years in the field, and manual and automated tools to enable experimentation. A series of case studies are presented to exemplify state-of-the-art workflows developed within our laboratories.

No abstract

Enantiopure C(1)-symmetric bis(imino)pyridine cobalt chloride, methyl, hydride, and cyclometalated complexes have been synthesized and characterized. These complexes are active as catalysts for the enantioselective hydrogenation of geminal-disubstituted olefins.

Oligomerization is kinetically favored in RCM reactions catalyzed by RuCl2(PCy3)(IMes)(CHPh), for a range of unhindered α,ω-dienes leading to large or medium-sized rings, even at dilutions designed to minimize intermolecular reaction. Reversible metathesis (i.e., ethenolysis) is inhibited by rapid volatilization of ethylene. At appropriately high dilutions, however, the RCM products are efficiently liberated by backbiting.